FDA
-
-
-
-
-
-
-
Humacyte prices $50 million stock offering at $1.05 per share
-
-
-
-
-
-
-
Humacyte ATEV shows superior results in dialysis access trial
-
-
-
-
-
-
-
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Humacyte names Jim Mercadante as chief commercial officer
-
-
-
-
-
-
-
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
-
-
-
-
-
-
-
Humacyte submits application for Symvess approval in Israel
-
-
-
-
-
-
-
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
-
326,541 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

